ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1305

Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) – a multicenter study

Nina Shirman1, Liora Harel2, Gil Amarilyo3, Kfir Kaidar4, Yonatan Butbul Aviel5, Merav Heshin Bekenstein6, Mohamad Hamad Saied7, Ofra Goldzweig8, Adi Miler9 and Yoel Levinsky10, 1Schneider children's medical center of Israe, Tel Aviv, Israel, 2Schneider Children's Medical center, Nettnja, Israel, 3Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, 4Pediatric rheumatology, Schneider children's medical center of Israel, Petah Tikva, Israel, 5Pediatric rheumatology, Technion Faculty of Medicine, Haifa, Israel, 6Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, 7Carmel Medical Centre, Technion Faculty of Medicine, Haifa, Israel, 8Pediatric rheumatology unit, Kaplan medical canter, Rehovot, Israel, 9Pediatric rheumatology unit, Technion Faculty of Medicine, Haifa, Israel, 10Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel

Meeting: ACR Convergence 2025

Keywords: Autoinflammatory diseases, corticosteroids, COVID-19, Inflammation, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1272–1305) Pediatric Rheumatology – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is an autoinflammatory disease following SARS-CoV-2 exposure. The optimal treatment strategy remains under investigation, though intravenous immunoglobulin (IVIG) and glucocorticoids are commonly used. While some authors suggest induction with pulse steroids, ACR guidelines recommend initiating low-to-moderate dose glucocorticoids (1-2 mg/kg). This study aimed to assess the response of patients treated with low-to-moderate dose corticosteroids and compare outcomes to a historical cohort treated with pulse steroids.

Methods: A multi-center, retrospective study collected data on patients initially treated with low-to-moderate dose corticosteroids. Clinical and laboratory data were compared to a historical cohort to assess disease severity and outcomes. The primary outcome was treatment escalation after 24 hours. Other outcomes included cardiovascular function, need for adjunctive therapies, and length of hospital stay.

Results: Among 41 patients receiving low-to-moderate dose corticosteroids, 7 (17.1%) required escalation. Overall, 13 (34.2%) needed vasopressors, and 2 (5.3%) required mechanical ventilation. Compared to 26 patients treated with pulse steroids, no differences were found in age, sex, fever characteristics, Kawasaki-like symptoms, or hemodynamic instability. Inflammatory markers (CRP, ESR) were similar, though ferritin was lower in the study group. Hospitalization was longer in the pulse steroid group. An echocardiogram performed post-recovery revealed that 87.5% of the study group had normal cardiac function.

Conclusion: Low-to-moderate dose glucocorticoids are effective for most MIS-C patients, with only 17% requiring escalation. No differences were seen in vasopressor or ventilation needs. Given shorter hospital stays and favorable cardiac outcomes, this approach seems appropriate, although pulse steroids may be considered in severe cases. Further research is needed to optimize dosing and duration of therapy.

Supporting image 1Table 1


Disclosures: N. Shirman: None; L. Harel: None; G. Amarilyo: None; K. Kaidar: None; Y. Butbul Aviel: None; M. Heshin Bekenstein: None; M. Hamad Saied: None; O. Goldzweig: None; A. Miler: None; Y. Levinsky: None.

To cite this abstract in AMA style:

Shirman N, Harel L, Amarilyo G, Kaidar K, Butbul Aviel Y, Heshin Bekenstein M, Hamad Saied M, Goldzweig O, Miler A, Levinsky Y. Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) – a multicenter study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/clinical-outcomes-of-low-to-moderate-dose-glucocorticoids-in-multisystem-inflammatory-syndrome-in-children-mis-c-a-multicenter-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-outcomes-of-low-to-moderate-dose-glucocorticoids-in-multisystem-inflammatory-syndrome-in-children-mis-c-a-multicenter-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology